Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

223742

registered interest
date	25/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Embryos
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 February (HL4885), whether the Human Fertilisation and Embryology Authority is required to maintain records regarding the size of embryos; if so, what is the mean, median and standard deviation for the diameter of (1) embryos transferred, (2) embryos stored for research, and (3) embryos allowed to perish; and if not, how providing a repeated reference to the size of an embryo has been considered to be relevant to the number of embryos destroyed when no such request for information regarding the size of embryos was previously made.
tabling member printed	Lord Alton of Liverpool
uin	HL5227
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>The Human Fertilisation and Embryology Authority has advised that it is not required to maintain records regarding the size of embryos.</p><p> </p><p> </p><p> </p><p>With regard to the size of the embryo, I refer the noble Lord to my answer of 24 February 2015 (<a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=4885" target="_blank">HL4885</a>).</p><p> </p> answering member printed Earl Howe question first answered 10/03/2015 15:07:02 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

223743

registered interest
date	25/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Embryos
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 February (HL4885), whether the reference to reconciliation work performed on the data by the Human Fertilisation and Embryology Authority (HFEA) indicates that previously supplied figures have been inaccurate; if so, what is the extent to which the HFEA has provided inaccurate information and who accepts responsibility for this; and why the embryos stored for research are not included among the number of embryos allowed to perish if embryos used in research are not allowed to persist beyond 14 days.
tabling member printed	Lord Alton of Liverpool
uin	HL5228
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>The Human Fertilisation and Embryology Authority has advised that data it has supplied in response to any given question is correct when it is provided. Such data may change slightly over time. The supplied figures were not inaccurate and responsibility for inaccuracy does not, therefore, arise. Embryos stored for research are not, by definition, perished until they are used.</p><p> </p> answering member printed Earl Howe question first answered 10/03/2015 12:48:07 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

223744

registered interest
date	25/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human-animal Hybrid Embryos
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans they now have to repeal those provisions of the Human Fertilisation and Embryology Act 2008 which permit the creation of animal-human hybrid embryos.
tabling member printed	Lord Alton of Liverpool
uin	HL5229
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>The Government has no plans to repeal the provisions in question.</p><p> </p> answering member printed Earl Howe question first answered 10/03/2015 12:47:35 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

223434

registered interest
date	24/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Naloxone
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what action they are taking to improve access to Naloxone in England.
tabling member printed	Lord Ramsbotham
uin	HL5187
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>Naloxone has a vital role in saving lives and we are committed to widening its use in England. We have accepted the recommendation from the Advisory Council on the Misuse of Drugs to make this life-saving medicine available more widely and Departmental officials are drafting new regulations to give effect to this decision. This legislative change is due to commence in October 2015.</p><p> </p><p> </p><p> </p><p>Public Health England has recently published advice for commissioners and providers on the provision of take-home naloxone for reversing overdose in people who use heroin and other opiates, so that commissioners and providers can take action, both now and following the October 2015 legislative change, to widen the supply of naloxone.</p><p> </p><p> </p><p> </p><p>In addition, the issue of naloxone supply is also being considered by the independent expert group updating the 2007 drug misuse clinical guidelines, Drug Misuse and Dependence: UK Guidelines on Clinical Management.</p><p> </p><p> </p><p> </p><p>As it is formulated as an injectable medicine, naloxone does not meet the criteria set out in legislation for classification as an over-the-counter medicine.</p><p> </p><p> </p><p> </p><p>Amended regulations will be publicly available when they are laid before Parliament.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5188 HL5189 question first answered 10/03/2015 12:49:21 answering member 2000 label Biography information for Earl Howe
tabling member	3744 label Biography information for Lord Ramsbotham

223435

registered interest
date	24/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Naloxone
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they have given consideration to making Naloxone an over-the-counter drug in England.
tabling member printed	Lord Ramsbotham
uin	HL5188
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>Naloxone has a vital role in saving lives and we are committed to widening its use in England. We have accepted the recommendation from the Advisory Council on the Misuse of Drugs to make this life-saving medicine available more widely and Departmental officials are drafting new regulations to give effect to this decision. This legislative change is due to commence in October 2015.</p><p> </p><p> </p><p> </p><p>Public Health England has recently published advice for commissioners and providers on the provision of take-home naloxone for reversing overdose in people who use heroin and other opiates, so that commissioners and providers can take action, both now and following the October 2015 legislative change, to widen the supply of naloxone.</p><p> </p><p> </p><p> </p><p>In addition, the issue of naloxone supply is also being considered by the independent expert group updating the 2007 drug misuse clinical guidelines, Drug Misuse and Dependence: UK Guidelines on Clinical Management.</p><p> </p><p> </p><p> </p><p>As it is formulated as an injectable medicine, naloxone does not meet the criteria set out in legislation for classification as an over-the-counter medicine.</p><p> </p><p> </p><p> </p><p>Amended regulations will be publicly available when they are laid before Parliament.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5187 HL5189 question first answered 10/03/2015 12:49:21 answering member 2000 label Biography information for Earl Howe
tabling member	3744 label Biography information for Lord Ramsbotham

223436

registered interest
date	24/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Naloxone
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether draft regulations for making Naloxone more widely available will be published in draft ahead of the October 2015 implementation, to enable organisations including police, hostels and drugs misuse services to make advance plans.
tabling member printed	Lord Ramsbotham
uin	HL5189
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>Naloxone has a vital role in saving lives and we are committed to widening its use in England. We have accepted the recommendation from the Advisory Council on the Misuse of Drugs to make this life-saving medicine available more widely and Departmental officials are drafting new regulations to give effect to this decision. This legislative change is due to commence in October 2015.</p><p> </p><p> </p><p> </p><p>Public Health England has recently published advice for commissioners and providers on the provision of take-home naloxone for reversing overdose in people who use heroin and other opiates, so that commissioners and providers can take action, both now and following the October 2015 legislative change, to widen the supply of naloxone.</p><p> </p><p> </p><p> </p><p>In addition, the issue of naloxone supply is also being considered by the independent expert group updating the 2007 drug misuse clinical guidelines, Drug Misuse and Dependence: UK Guidelines on Clinical Management.</p><p> </p><p> </p><p> </p><p>As it is formulated as an injectable medicine, naloxone does not meet the criteria set out in legislation for classification as an over-the-counter medicine.</p><p> </p><p> </p><p> </p><p>Amended regulations will be publicly available when they are laid before Parliament.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5187 HL5188 question first answered 10/03/2015 12:49:21 answering member 2000 label Biography information for Earl Howe
tabling member	3744 label Biography information for Lord Ramsbotham

222723

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Giant Cell Arteritis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what estimate they have made of the costs to the National Health Service of failures to diagnose giant cell arteritis sufficiently early to prevent loss of vision for those afflicted, in each of the last five years.
tabling member printed	Lord Wills
uin	HL5064
answer	answer is ministerial correction date of answer 06/03/2015 answer text <p>The National Institute for Heath and Care Excellence Clinical Knowledge Summary on Giant Cell Arteritis (GCA) sets out that the annual incidence of GCA in the United Kingdom is approximately 20 per 100,000 people, with total or partial vision loss affecting up to 20% of people. Numbers of patients diagnosed as suffering from GCA related sight loss in each of the last five years and its associated costs are not available.</p><p> </p><p> </p><p> </p><p>No specific assessment has been made of the GCA clinical pathway used in Southend. However, the Government understands that Professor Bhaskar Dasgupta who developed the Southend clinical pathway, contributed to development of the Royal College of Physicians’ guideline on GCA, published in 2010. The guideline sets out best practice for clinicians in the prompt diagnosis and urgent management of GCA, helping to minimise GCA related vision loss.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5065 HL5067 question first answered 06/03/2015 10:52:58 answering member 2000 label Biography information for Earl Howe
tabling member	260 label Biography information for Lord Wills

222724

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Giant Cell Arteritis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what estimate they have made of the number of people afflicted by giant cell arteritis who have lost vision as a result of a failure to diagnose the illness sufficiently early, in each of the last five years.
tabling member printed	Lord Wills
uin	HL5065
answer	answer is ministerial correction date of answer 06/03/2015 answer text <p>The National Institute for Heath and Care Excellence Clinical Knowledge Summary on Giant Cell Arteritis (GCA) sets out that the annual incidence of GCA in the United Kingdom is approximately 20 per 100,000 people, with total or partial vision loss affecting up to 20% of people. Numbers of patients diagnosed as suffering from GCA related sight loss in each of the last five years and its associated costs are not available.</p><p> </p><p> </p><p> </p><p>No specific assessment has been made of the GCA clinical pathway used in Southend. However, the Government understands that Professor Bhaskar Dasgupta who developed the Southend clinical pathway, contributed to development of the Royal College of Physicians’ guideline on GCA, published in 2010. The guideline sets out best practice for clinicians in the prompt diagnosis and urgent management of GCA, helping to minimise GCA related vision loss.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5064 HL5067 question first answered 06/03/2015 10:52:58 answering member 2000 label Biography information for Earl Howe
tabling member	260 label Biography information for Lord Wills

222725

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Innovation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what steps they are taking to encourage innovation by National Health Service clinicians.
tabling member printed	Lord Wills
uin	HL5066
answer	answer is ministerial correction date of answer 09/03/2015 answer text <p><em>Innovation Health and Wealth</em>, published in 2011, set out a number of steps to encourage innovation which the National Health Service is pursuing. The National Institute for Health and Care Excellence (NICE) Implementation Collaborative supports faster and more consistent access to NICE recommended medicines, treatments and technologies. Academic Health Science Networks are working with their local health systems to support the effective adoption of innovation.</p><p> </p><p> </p><p> </p><p>Building on this, we are working closely with NHS England, industry and other key stakeholders to develop the Innovation Scorecard to make it a more effective tool for identifying unjustified variation in uptake of innovative treatments in the NHS. Following the vision set out in the <em>Five Year Forward View</em>, we are also working with NHS England to support the development of ‘test beds’, which will offer the opportunity to test technologies at scale in a real world setting.</p><p> </p><p> </p><p> </p><p>We have also announced the Innovative Medicines and Medical Technologies review, which will make recommendations to accelerate the overall pathway, including adoption and diffusion of innovation in the NHS.</p><p> </p> answering member printed Earl Howe question first answered 09/03/2015 16:20:07 answering member 2000 label Biography information for Earl Howe
tabling member	260 label Biography information for Lord Wills

222726

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Polymyalgia Rheumatica and Giant Cell Arteritis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the pilot clinical pathway in Southend to develop faster and more effective diagnosis of polymyalgia rheumatica and giant cell arteritis.
tabling member printed	Lord Wills
uin	HL5067
answer	answer is ministerial correction date of answer 06/03/2015 answer text <p>The National Institute for Heath and Care Excellence Clinical Knowledge Summary on Giant Cell Arteritis (GCA) sets out that the annual incidence of GCA in the United Kingdom is approximately 20 per 100,000 people, with total or partial vision loss affecting up to 20% of people. Numbers of patients diagnosed as suffering from GCA related sight loss in each of the last five years and its associated costs are not available.</p><p> </p><p> </p><p> </p><p>No specific assessment has been made of the GCA clinical pathway used in Southend. However, the Government understands that Professor Bhaskar Dasgupta who developed the Southend clinical pathway, contributed to development of the Royal College of Physicians’ guideline on GCA, published in 2010. The guideline sets out best practice for clinicians in the prompt diagnosis and urgent management of GCA, helping to minimise GCA related vision loss.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5064 HL5065 question first answered 06/03/2015 10:52:58 answering member 2000 label Biography information for Earl Howe
tabling member	260 label Biography information for Lord Wills